Read more: Manuel A. Navia, Ph.D. Axel Unterbeck, Ph.D. B. Christopher Kim, Ph.D. David Armistead, Ph.D.
Investment Type: Venture Capital
Mentions in press and media 10
| Date | Title | Description |
| 02.04.2012 | Former head of Sanofi vaccines division becomes infectious disease biotech CEO | Last year, it was granted a five-year research grant valued up to $196 million by the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services, to fund the development of seasonal and ... |
| 30.03.2009 | Pathway Medical lands generous $40M to treat arterial disease | Pathway Medical Technologies, maker of a non-invasive catheter capable of removing all kinds of artery blockages and build-up, says it just scored $40 million in a fourth round of funding — a pretty high figure for a life science device man... |
| 20.03.2009 | Surprised? Oxford Bioscience Partners Lands, Briefly, on Dreaded List of “VC Walking Dead” | Share Share on Facebook Share on Twitter LinkedIn Email Reprints It’s always slightly shocking to find out that a perceived wealthy friend or colleague isn’t so well off. I felt much the same way yesterday about seeing biotech venture firm ... |
| 02.02.2009 | New England VCs Well Down Midas List—Oxford’s Fambrough Leads Pack | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Mike Moritz, John Doerr. John Doerr, Mike Moritz. It seems like those two Silicon Valley names perennially head Forbes’ Midas List of top VCs, often taking turns in the No. 1 ... |
| 08.01.2009 | Concentric Medical closes $15M to ease stroke symptoms | Concentric Medical, developer of minimally invasive devices used to remove blood clots in ischemic stroke patients, took $15 million in new venture backing to expand its product portfolio and run more clinical trials. The Mountain View, Cal... |
| 14.10.2008 | Migraine sufferers look elsewhere as Cierra buckles | The headache is over for medical device maker Cierra. Actually it’s all over. The Redwood City, Calif.-based company is out of business after failing to draft enough participants into a clinical trial of a catheter-based technology purporte... |
| 07.06.2007 | Amgen snaps up another biotech startup, Alantos Pharma, for $300M | Amgen suddenly has a voracious appetite for startups. In its second deal this week, the biotech giant acquired Cambridge, Mass., biotech Alantos Pharmaceuticals for $300 million in cash. (The release is here.) Founded in Heidelberg, Germany... |
| 04.05.2007 | Cancer-drug maker Aveo raises $53M | Aveo Pharmaceuticals, a Cambridge, Mass. cancer-drug company, raised $53 million in a fourth round of funding from a coalition of mostly blue-chip life-science investors. New investors included Biogen Idec, Bessemer Venture Partners, Merlin... |
| 29.09.2004 | Amadeus leads $14.4 million Series B financing in Solexa | Amadeus leads $14.4 million Series B financing in Solexa 29-09-2004 Amadeus Capital Partners has led a Series B financing of $14. 4 million in Solexa Ltd., a company at the forefront of developing systems that will allow the rapid sequencin... |
| - | Former head of Sanofi vaccines division becomes infectious disease biotech CEO | The former head of Sanofi’s (NYSE:SNY) vaccines division, one of the largest vaccine companies in the world, has joined a biotechnology company developing infectious disease vaccines as its CEO. Wayne Pisano will lead Cranbury, New Jersey-b... |